Titlebook: Breast Cancer; A Guide to Clinical Adnan Aydiner,Abdullah Igci,Atilla Soran Book 2019 Springer Nature Switzerland AG 2019 breast disease.c

foresight

書(shū)目名稱Breast Cancer影響因子(影響力)




書(shū)目名稱Breast Cancer影響因子(影響力)學(xué)科排名




書(shū)目名稱Breast Cancer網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱Breast Cancer網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱Breast Cancer被引頻次




書(shū)目名稱Breast Cancer被引頻次學(xué)科排名




書(shū)目名稱Breast Cancer年度引用




書(shū)目名稱Breast Cancer年度引用學(xué)科排名




書(shū)目名稱Breast Cancer讀者反饋




書(shū)目名稱Breast Cancer讀者反饋學(xué)科排名

象形文字

Eva Below,Wolfram Ebinger,Ulrich Pramannreast as a primary lesion, including liposarcoma, leiomyosarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, and osteosarcoma. Fibroepithelial tumors are biphasic neoplasms characterized by the proliferation of both epithelial and mesenchymal elements. Fibroadenoma and phyllodes tumors constitute the major entities.

Homocystinuria

鎮(zhèn)痛劑

exorbitant

Nuclear Medicine Imaging in Breast Canceraging with PET is a rapidly emerging approach in breast cancer, conventional single-photon nuclear medicine imaging, including bone scintigraphy and sentinel lymph node scintigraphy, still has an important role in the management of breast cancer. This chapter outlines the role of nuclear medicine imaging in patients with breast cancer.

小爭(zhēng)吵

indecipherable

In Situ Cancer Treatmentof invasive breast cancer. This chapter focuses on recommendations for workup, primary treatment, risk reduction strategies, and surveillance specific to carcinoma in situ, which represents approximately 20% of all breast cancers diagnosed by mammography.

FRET

被告

Intraoperative Pathological Examination of Breast Lesionsmethod is typically either frozen section (FS) or cytology in addition to gross examination, although some molecular techniques have recently been developed for intraoperative pathological examination (IPE).

Guaff豪情痛飲

Prognostic and Predictive Factorshese assays are based on the identification of prognostic gene signatures by using microarrays. Many groups have attempted to develop genomic tests based on genomic profiling to improve the prediction of clinical outcome compared with standard pathological and clinical markers.